A5019916450- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Protease and Inhibitor Mechanisms
- Neurofibromatosis and Schwannoma Cases
- Radiopharmaceutical Chemistry and Applications
- Signaling Pathways in Disease
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Melanoma and MAPK Pathways
- Cancer, Lipids, and Metabolism
- Nutrition and Health in Aging
- HER2/EGFR in Cancer Research
- Cardiac tumors and thrombi
- Head and Neck Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
Essen University Hospital
2016-2025
Deutschen Konsortium für Translationale Krebsforschung
2022-2025
University of Duisburg-Essen
2020-2024
German Cancer Research Center
2022-2023
West Cancer Center
2023
Abstract Purpose: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, other cancer entities. Experimental Design: Up to four cycles radioligand therapy (RLT) were offered (i) progressive metastatic malignancy, (ii) exhaustion approved therapies, (iii) high fibroblast activation protein (FAP) expression, defined as SUVmax ≥ 10 more than 50% tumor. Primary endpoint was RECIST response after RLT. Secondary endpoints...
Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid high uptake of small-molecule inhibitors FAP (68Ga-FAPI-46) PET imaging. Here, we report our initial experience the feasibility safety 90Y-FAPI-46 radioligand therapy extensively pretreated patients with tumors. Methods: Patients were considered if they showed both exhaustion all approved...
Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern FAPα solitary fibrous tumor (SFT) and its potential use as a radiotheranostic target. <b>Methods:</b> We analyzed messenger RNA biopsy samples from SFT patients using immunohistochemistry multiplexed immunofluorescence. Tracer uptake detection efficacy were assessed undergoing clinical <sup>68</sup>Ga-FAPα inhibitor (FAPI)–46 PET,<sup>18</sup>F-FDG PET,...
•We show the applicability of a deep learning-based workflow for body composition analysis in three German cancer centers.•Automatically extracted markers from routine CT scans were comparable between cohorts.•CT-derived sarcopenia and myosteatosis associated with OS pooled cohort.•In subgroup, anemia, hypoproteinemia, inflammation. BackgroundDespite prognostic relevance cachexia pancreatic cancer, individual has not been routinely integrated into treatment planning. In this multicenter...
•We developed a machine-learning-based prediction model that outperforms the AJCC staging system and mGPS.•Applying our to an external validation cohort demonstrates generalizability.•Explainable machine learning enables understand decision making of identifies relevant parameters.•Combining clinical, imaging genetic data holds potential for personalized prognostication in advanced PDAC. BackgroundExisting risk scores appear insufficient assess individual survival patients with pancreatic...
Cancer of unknown primary (CUP) is a heterogeneous entity with limited overall survival (OS) in most patients. Prognostic biomarkers are needed, particularly for treatment stratification. We investigated the impact programmed death-ligand 1 (PD-L1) expression as prognostic marker immunotherapy-naïve CUP
The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform about outcomes across different lines treatment. This retrospective analysis aims evaluate patient at a large German referral center over the past 15 years.
11536 Background: Despite long-lasting responses to imatinib most metastatic gastrointestinal stromal tumors (GIST) eventually progress and subsequent treatments are associated with limited duration of disease control. Ponatinib is a potent KIT inhibitor strong activity against secondary mutations in exon 17, including the highly resistant D816 KIT. Based on dose-depending toxicity profile we sought evaluate safety lower dosing (30mg) ponatinib pretreated patients KIT-mutant GIST. We here...
Systemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated patients with iCCA treated systemic chemotherapy. Therefore, we the impact of SIR on clinical course advanced at our center.SIR were retrospectively 219 West-German-Cancer-Center Essen from 2014 to 2019. Markers included neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte (LMR), CRP, and modified Glasgow-Prognostic-Score (mGPS), which correlated...
Circulating tumor DNA (ctDNA) from circulating free (cfDNA) in GIST is of interest for the detection heterogeneous resistance mutations and treatment monitoring. However, methodologies use a local setting are not standardized error-prone difficult to interpret. We established workflow evaluate routine tissue NGS (Illumina-based next generation sequencing) panels pipelines ctDNA sequencing an academic setting. Regular blood collection (Sarstedt) EDTA tubes were sufficient direct processing...
Patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) have a dismal prognosis. The best strategies in these patients remain elusive. Against this background, we report the clinical course of mCRC to retrieve treatment strategy.Clinico-pathological data were extracted from electronic health records. Kaplan-Meier method was used estimate overall (OS) and progression-free survival (PFS). Objective response rate (ORR) assessed according RECIST 1.1.In total, 51 enrolled. FOLFOXIRI...
Systemic therapy is firmly established in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Clinical efficacy still modest and options are limited. Combination protocols such as FOLFIRINOX gemcitabine/nab-paclitaxel (Gem/NP) define standard-of-care. Patients may receive a sequence of both regimens first- second-line palliative treatment. However, there no guidance regarding preferred order.This retrospective analysis clinical characteristics, treatment...
Supplementary Figure from Safety and Efficacy of <sup>90</sup>Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma Other Cancer Entities
Supplementary Figure from Safety and Efficacy of <sup>90</sup>Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma Other Cancer Entities